Recent clinical trials in patients with heart failure with preserved ejection fraction (HFpEF) have provided important insights into participant selection strategies. Historically, HFpEF trials have included patients with relatively preserved left ventricular ejection fraction ranging from 40% to 55% and a clinical history of heart failure. Contemporary HFpEF trials have also incorporated inclusion criteria such as hospitalization for HFpEF, altered functional capacity, cardiac structural and functional abnormalities, and abnormalities in neurohormonal status (e.g., elevated natriuretic peptide levels). Careful analyses of the effect of these patient selection criteria on outcomes in prior trials provide valuable lessons for future trial design. We review recent and ongoing HFpEF clinical trials from a patient selection perspective and appraise trial patient selection methodologies in relation to outcomes. This review reflects discussions between clinicians, scientists, trialists, regulators, and regulatory representatives at the 10th Global CardioVascular Clinical Trials Forum in Paris, France, on December 6, 2013. (J Am Coll Cardiol 2015;65:1668–82) © 2015 by the American College of Cardiology Foundation.
have been neutral. Important lessons can be learned from these prior trials. In this paper, we summarize recent and ongoing HFpEF clinical trials and appraise trial methodologies from the perspective of patient selection to critically inform the design of future randomized clinical trials for clinicians, researchers, and patients.

GUIDELINE DEFINITIONS FOR HFpEF

Recommendations for the diagnosis of patients with HFpEF are similar in scope and depth across the most recent U.S. and European guidelines (6–9). The most recent American College of Cardiology/American Heart Association guidelines defined HFpEF as patients with ejection fraction (EF) >50% with symptoms suggestive of HF and exclusion of other potential noncardiac etiologies of HF. The guidelines also include subpopulations of borderline HFpEF with EF 41% to 49% and HFpEF with improved EF >40% for patients who previously had reduced EF (6). The 2012 European Society of Cardiology guidelines defined 4 requirements to diagnose HFpEF, including: 1) symptoms typical of HF; 2) signs typical of HF; 3) normal or only mildly reduced left ventricular EF without left ventricular dilation; and 4) relevant structural heart disease (left ventricular hypertrophy/left atrial enlargement) and/or diastolic dysfunction (Table 1) (8,9). The underlying pathophysiologic mechanisms behind HFpEF involve, in part, a diffuse inflammatory state that develops from the constellation of such frequently coexisting comorbidities as chronic obstructive lung disease, anemia, diabetes mellitus, renal dysfunction, and obesity in patients with HFpEF (10,11). The proinflammatory state limits the available nitric oxide in the coronary microvasculature and shifts cardiac remodeling toward hypertrophy and interstitial fibrosis, which increases left ventricular diastolic stiffness and the conditions for HFpEF (12).

DEFINITIONS IN CLINICAL TRIALS

The first large clinical trial that focused on patients with HFpEF, the CHARM (Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity) Preserved trial, required an EF >40%, New York Heart Association (NYHA) functional class II to IV symptoms for >4 weeks, and any prior hospital admission for a cardiac reason (13). This definition was analogous to HFrEF trials at the time, where EF cutpoints <35% and <45% were used in addition to HF symptoms or known history of HF (14,15). As the results from clinical trials and secondary analyses in these HFpEF populations without use of guideline criteria revealed low event rates and limited benefits from traditional HF therapies, clinical trials subsequently adjusted entry criteria (16). The EF criterion was increased, echocardiographic parameters were incorporated, and eventually, natriuretic peptide (NP) levels were included in a combined definition that also required HF symptoms (Table 2). Preserved EF >50%, symptoms and/or hospitalization for HF, echocardiographic findings, and elevated NP levels exemplified the prevailing thought that HFpEF was primarily a disease of elderly women with stiff left ventricles from longstanding hypertension and concomitant diabetes mellitus. However, clinical trials, cohort studies, and registry analyses have demonstrated that the HFpEF population is heterogeneous, particularly with respect to comorbidities (11). Future clinical trials in HFpEF may benefit from further refinement of these key patient selection criteria to optimize the potential for success.

EJECTION FRACTION

EF was the first inclusion criterion used to differentiate patients with HFrEF from HFpEF. The first 3 large HFpEF trials studied renin-angiotensin aldosterone system inhibition with EF cutoffs of 40% to 45% (13,17,18). More recent trials have split between using an EF cutoff ≥45% and ≥50%. The PARAMOUNT (Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection fraction) and TOPCAT (Treatment of
Preserved Cardiac Function HF Aldosterone Antagonist trial) trials used an EF cutoff for participant inclusion of ≥45% (19,20). This cutoff choice between trials in HFrEF and HFpEF has left a largely unstudied intermediate EF group including 10% to 15% (5,21) of the overall HF population with an EF between 40% and 50%. The CHARM pooled analyses and the American Heart Association’s GWTG-HF (Get With the Guidelines–Heart Failure) initiative have a bell-shaped EF distribution with 17% (n = 1,295) and 14% (n = 15,184) of patients with an EF of 40% to 50%, respectively (5). However, the OPTIMIZE-HF (Organized Program to Initiate Life-saving Treatment in Hospitalized Patients with Heart Failure) Registry and Olmstead County study have bimodal EF distributions, with relatively few patients with an EF of 40% to 50%, suggesting that real-world populations may have fewer patients in this intermediate range than clinical trials (4,21,22).

The clinical characteristics and clinical outcomes of patients with an EF between 40% and 50% appear to be intermediate compared with patients with HFrEF and HFpEF, and the etiology of the mild reduction in EF varies (partial EF recovery or primary HFpEF) (21-23).

It is unknown which EF cutoff provides the most reliable discriminator to enhance enrollment of the HFpEF phenotype and associated event rates. The MAGGIC (Meta-analysis Global Group in Chronic Heart Failure) meta-analysis demonstrated a clear increase in event rates when EF <40% was compared with >40% (24). The utility of this EF cutpoint was also demonstrated in the OPTIMIZE-HF registry, where multivariable analyses revealed that in-hospital mortality risk for patients with EF between 40% and 50% was similar to those with EF >50%.

Specifically, in-hospital mortality decreased by 17% for every 10% increase in EF up to 38%, with no further association with increased mortality above an EF of 38% (22). The CHARM pooled analyses demonstrated an increased risk for all-cause mortality and cardiovascular death with EF <45% (25).

When event rates in the CHARM pooled analyses were evaluated for patients with HFpEF using an EF ≥40% and repeating the same analysis with an EF ≥50%, the event rates were unchanged (26). A secondary analysis from SENIORS (Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure) revealed similar primary event rates for patients with HFpEF defined on the basis of an EF ≥35% or ≥40% (27). The placebo arms of HF clinical trials using lower EF cutoffs, such as EF >40%, reveal similar event rates to clinical trials with EF cutoffs ≥45% or ≥50% (Table 2). Although the event rates from the placebo arms across EF cutoffs from 40% to 50% are similar, using an EF cutoff of ≥40% or ≥45% risks including patients with an intermediate EF who may have different characteristics, such as more ischemic heart disease.

The historical precedence for using EF cutoffs for HFrEF <40% or ≥35% versus ≥40%, 45%, or 50% for HFpEF, combined with equal event rates across a range of EFs ≥40% to 50%, leaves us with 3 future clinical design options, including: 1) using an EF ≥40% to prevent an intermediate EF gap; 2) using a higher EF of ≥45% or ≥50% and defining the created intermediate EF group; or 3) lessening the effect of EF as an inclusion criterion. There is no clear absolute EF inclusion criterion; however, insightful use of EF as an inclusion criterion with an eye toward the preferred HFpEF phenotype will lead to successful trials. For example, if a clinical trial is studying a pharmaceutical therapy aimed at HFpEF patients with hypertension and associated structural remodeling, then use of a higher EF (e.g., 50%) inclusion criterion will enrich the trial with the preferred phenotype. However, if a promising new therapy appears to work across a more heterogeneous HFpEF population, then use of a lower EF (e.g., 40%) inclusion criterion will potentially make the results of the trial generalizable. Ultimately, the use of EF as an inclusion criterion requires appropriate insight into the HFpEF phenotype that will benefit most from the therapy under investigation.

### Table 1: Summary of HFpEF Diagnosis Guidelines

<table>
<thead>
<tr>
<th>Guidelines</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESC (9)</td>
<td>The following 4 criteria are required: 1) symptoms typical of HF; 2) signs typical of HF; 3) normal or only mildly reduced LVEF and LV not dilated; and 4) relevant structural heart disease (LV hypertrophy/LA enlargement) and/or diastolic dysfunction.</td>
</tr>
<tr>
<td>ACC/AHA:</td>
<td>Diastolic HF. Multiple criteria have been used; exclude other potential noncardiac causes of symptoms suggestive of HF.</td>
</tr>
</tbody>
</table>
| HFpEF (6)  | ALL EF ≤45% for HFrEF and HFpEF, and the etiology of the mild patient with an EF between 40% and 50%, suggesting that real-world populations may have fewer patients in this intermediate range than clinical trials (4,21,22). The clinical characteristics and clinical outcomes of patients with an EF between 40% and 50% appear to be intermediate compared with patients with HFrEF and HFpEF, and the etiology of the mild reduction in EF varies (partial EF recovery or primary HFpEF) (21-23). It is unknown which EF cutoff provides the most reliable discriminator to enhance enrollment of the HFpEF phenotype and associated event rates. The MAGGIC (Meta-analysis Global Group in Chronic Heart Failure) meta-analysis demonstrated a clear increase in event rates when EF <40% was compared with >40% (24). The utility of this EF cutpoint was also demonstrated in the OPTIMIZE-HF registry, where multivariable analyses revealed that in-hospital mortality risk for patients with EF between 40% and 50% was similar to those with EF >50%. Specifically, in-hospital mortality decreased by 17% for every 10% increase in EF up to 38%, with no further association with increased mortality above an EF of 38% (22). The CHARM pooled analyses demonstrated an increased risk for all-cause mortality and cardiovascular death with EF <45% (25). When event rates in the CHARM pooled analyses were evaluated for patients with HFpEF using an EF ≥40% and repeating the same analysis with an EF ≥50%, the event rates were unchanged (26). A secondary analysis from SENIORS (Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure) revealed similar primary event rates for patients with HFpEF defined on the basis of an EF ≥35% or ≥40% (27). The placebo arms of HF clinical trials using lower EF cutoffs, such as EF >40%, reveal similar event rates to clinical trials with EF cutoffs ≥45% or ≥50% (Table 2). Although the event rates from the placebo arms across EF cutoffs from 40% to 50% are similar, using an EF cutoff of ≥40% or ≥45% risks including patients with an intermediate EF who may have different characteristics, such as more ischemic heart disease.

The historical precedence for using EF cutoffs for HFrEF <40% or ≥35% versus ≥40%, 45%, or 50% for HFpEF, combined with equal event rates across a range of EFs ≥40% to 50%, leaves us with 3 future clinical design options, including: 1) using an EF ≥40% to prevent an intermediate EF gap; 2) using a higher EF of ≥45% or ≥50% and defining the created intermediate EF group; or 3) lessening the effect of EF as an inclusion criterion. There is no clear absolute EF inclusion criterion; however, insightful use of EF as an inclusion criterion with an eye toward the preferred HFpEF phenotype will lead to successful trials. For example, if a clinical trial is studying a pharmaceutical therapy aimed at HFpEF patients with hypertension and associated structural remodeling, then use of a higher EF (e.g., 50%) inclusion criterion will enrich the trial with the preferred phenotype. However, if a promising new therapy appears to work across a more heterogeneous HFpEF population, then use of a lower EF (e.g., 40%) inclusion criterion will potentially make the results of the trial generalizable. Ultimately, the use of EF as an inclusion criterion requires appropriate insight into the HFpEF phenotype that will benefit most from the therapy under investigation. |
<table>
<thead>
<tr>
<th>Trial (Ref. #)</th>
<th>Clinical Dx HF</th>
<th>Prior HF Admission, %</th>
<th>EF, %</th>
<th>Atrial Fibrillation/Flutter, %</th>
<th>BNP,* pg/ml</th>
<th>NT-proBNP,* pg/ml</th>
<th>Event Rate† (1 yr)</th>
<th>Primary Endpoint</th>
<th>Clinical Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHARM-PRESERVED (13)</td>
<td>NYHA II to IV &gt;4 weeks, hospitalized for cardiac reason, history of hospital admission for cardiac reason</td>
<td>68.8</td>
<td>&gt;40</td>
<td>29.3</td>
<td>–</td>
<td>–</td>
<td>9.1%</td>
<td>CV death or HF hospitalization</td>
<td>No reduction in CV death; fewer patients in treatment group had HF hospitalization</td>
</tr>
<tr>
<td>PEP-CHF (17)</td>
<td>Age ≥70 yrs, on diuretics, echo with DD, 3 of 9 clinical, 2 of 4 echo criteria, CV hospitalization within 6 months</td>
<td>100</td>
<td>&gt;40</td>
<td>22</td>
<td>–</td>
<td>–</td>
<td>453</td>
<td>13.2%</td>
<td>Composite of all-cause mortality and unplanned HF hospitalization</td>
</tr>
<tr>
<td>DIG-PEF (87)</td>
<td>NSR, HF symptoms</td>
<td>–</td>
<td>&gt;45</td>
<td>0</td>
<td>–</td>
<td>–</td>
<td>7.8 per 100 patient-yrs</td>
<td>Combined HF hospitalization or HF mortality</td>
<td>Digoxin had no effect on mortality or all-cause CV hospitalization</td>
</tr>
<tr>
<td>SENIORS (27)</td>
<td>Age ≥70 yrs, HF history + ≥1 HF hospitalization, or EF ≤35% within past 6 months</td>
<td>–</td>
<td>&gt;35</td>
<td>37.1</td>
<td>–</td>
<td>–</td>
<td>19.2 per 100 patient-yrs</td>
<td>All-cause mortality or CV hospitalizations</td>
<td>No difference in effect of nebivolol on elderly patients with HFrEF vs. HFpEF</td>
</tr>
<tr>
<td>I-PRESERVE (18)</td>
<td>NYHA functional class II-IV</td>
<td>44</td>
<td>≥45</td>
<td>17</td>
<td>–</td>
<td>–</td>
<td>320</td>
<td>10.5 per 100 patient-yrs</td>
<td>All-cause mortality or CV hospitalization</td>
</tr>
<tr>
<td>ELANDD (88)</td>
<td>NYHA functional class II-III, echo DD</td>
<td>–</td>
<td>&gt;45</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>126</td>
<td>Change in 6MWD after 6 months</td>
<td>No change in 6MWD or peak VO₂</td>
</tr>
<tr>
<td>J-DHF (89)</td>
<td>Modified Framingham criteria for HF within 12 months</td>
<td>60</td>
<td>&gt;40</td>
<td>45.6</td>
<td>235 (mean)</td>
<td>–</td>
<td>8.5 per 100 patient-yrs</td>
<td>Composite of CV death and unplanned HF hospitalization</td>
<td>No improvement from carvedilol</td>
</tr>
<tr>
<td>ALDO-DHF (51)</td>
<td>Ambulatory NYHA functional class II-III HF, echo DD</td>
<td>36</td>
<td>≥50</td>
<td>4</td>
<td>–</td>
<td>–</td>
<td>148</td>
<td>Coprimary: change in diastolic function (E/e’), peak VO₂ at 12 months</td>
<td>Improved DD but no change in peak VO₂</td>
</tr>
<tr>
<td>Ex-DHF (90)</td>
<td>Symptomatic NYHA functional class II-III outpatients, age ≥45 yrs, DD grade ≥1, NSR, 1 CV risk factor</td>
<td>–</td>
<td>≥50</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>Change in peak VO₂ after 3 months</td>
<td>Peak VO₂ increased 3.3 ml/min/kg, E/e’ and LAVI decreased</td>
</tr>
<tr>
<td>PARAMOUNT (20)</td>
<td>NYHA functional class II-IV</td>
<td>45</td>
<td>≥45</td>
<td>43</td>
<td>–</td>
<td>&gt;400</td>
<td>–</td>
<td>Change in NT-proBNP from BL to 12 weeks</td>
<td>LCZ696 reduced NT-proBNP more than valsartan at 12 weeks</td>
</tr>
<tr>
<td>RELAX (50)</td>
<td>Stable outpatients with HF, elevated NT-proBNP, or elevated filling pressures, reduced exercise capacity</td>
<td>39</td>
<td>≥50</td>
<td>50</td>
<td>–</td>
<td>–</td>
<td>648</td>
<td>–</td>
<td>Change in peak VO₂ after 24 weeks of therapy</td>
</tr>
</tbody>
</table>

Continued on the next page
<table>
<thead>
<tr>
<th>Trial (Ref. #)</th>
<th>Clinical Dx HF</th>
<th>Prior HF Admission, %</th>
<th>EF, %</th>
<th>Atrial Fibrillation/ Atrial Flutter, %</th>
<th>BNP, pg/ml</th>
<th>NT-proBNP, pg/ml</th>
<th>Event Rate† (1 yr)</th>
<th>Primary Endpoint</th>
<th>Clinical Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>RELAX-AHF (91)</td>
<td>Admitted for AHF (dyspnea at rest or minimum exertion, pulmonary congestion on chest radiograph, and BNP ≥350 pg/ml or NT-proBNP ≥1,400 pg/ml and eGFR 30–75 ml/min/1.73 m²)</td>
<td>29.5</td>
<td>≥50</td>
<td>61.2</td>
<td>–</td>
<td>3,992</td>
<td>12.8%†</td>
<td>Change from BL in VAS-AUC to day 5 and proportion of patients with improved dyspnea by Likert scale</td>
<td>Improved dyspnea relief by the VAS-AUC and Likert scale</td>
</tr>
<tr>
<td>RAAM-PEF (92)</td>
<td>NYHA functional class II–III, clinical HF, and BNP ≥100 pg/ml within 2 months</td>
<td>60.9</td>
<td>≥50</td>
<td>13</td>
<td>284</td>
<td>–</td>
<td>–</td>
<td>Change in 6MWD</td>
<td>No change in 6MWD</td>
</tr>
<tr>
<td>SHIFT-PRESERVED (68)</td>
<td>Signs or symptoms of HF, echo with DD, exercise capacity &lt;80% age/sex predicted, E/e’ &gt;13 after exercise</td>
<td>–</td>
<td>≥50</td>
<td>–</td>
<td>62</td>
<td>–</td>
<td>–</td>
<td>Exercise capacity, E/e’</td>
<td>Improved peak VO₂ and improved E/e’ after exercise</td>
</tr>
<tr>
<td>TOPCAT (19)</td>
<td>History of hospitalization within the previous 12 months, with management of HF a major component of the care provided or an elevated NP level within 60 days before randomization</td>
<td>71.5</td>
<td>≥45</td>
<td>≥100</td>
<td>235</td>
<td>&gt;360</td>
<td>1,017</td>
<td>6.6 per 100 patient-yrs</td>
<td>Composite of CV mortality, aborted cardiac arrest, or hospitalization for HF</td>
</tr>
<tr>
<td>PARAGON-HF (93)</td>
<td>NYHA functional class II–IV requiring treatment with diuretic agents for ≥30 days, LAE or LVH by echo, and HF hospitalization within 9 months or elevated NT-proBNP</td>
<td>–</td>
<td>≥45</td>
<td>–</td>
<td>–</td>
<td>Elevated</td>
<td>–</td>
<td>Composite endpoint of CV death and total HF hospitalizations (first and recurrent)</td>
<td>–</td>
</tr>
<tr>
<td>SOCRATES-PRESERVED (94)</td>
<td>Worsening HF requiring hospitalization or IV diuretic agent as outpatient</td>
<td>–</td>
<td>≥45</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>NT-proBNP from BL to 12 weeks, change of LAVI, safety</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>EDIFY (95)</td>
<td>Stable symptomatic NYHA functional class II–III ≥3 months, HR in sinus rhythm ≥70, E/e’ &gt;13 or e’ lateral &lt;10 cm/s and e’ septal &lt;8 cm/s, or LAVI &gt;34 ml/m²</td>
<td>–</td>
<td>≥45</td>
<td>–</td>
<td>≥80</td>
<td>≥220</td>
<td>–</td>
<td>Diastolic function (E/e’), NT-proBNP, and 6MWD</td>
<td>–</td>
</tr>
</tbody>
</table>

Continued on the next page
<table>
<thead>
<tr>
<th>Trial (Ref. #)</th>
<th>Clinical Dx HF</th>
<th>Prior HF Admission, %</th>
<th>EF, %</th>
<th>Atrial Fibrillation/ Atrial Flutter, %</th>
<th>BNP, pg/ml</th>
<th>NT-proBNP, pg/ml</th>
<th>Event Rate‡ (1 yr)</th>
<th>Primary Endpoint</th>
<th>Clinical Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ontario, Canada (29)</td>
<td>1st time admission for HF (only) on the basis of Framingham HF criteria</td>
<td>–</td>
<td>&gt;50</td>
<td>31.8</td>
<td>–</td>
<td>–</td>
<td>22.2%</td>
<td>Death from any cause after the index hospitalization for HF</td>
<td>31.1% composite 1-yr mortality or readmission for HF, 22.2% 1-yr mortality, 13.5% 1-yr readmission for HF, 9.4% 30-day mortality or readmission for HF</td>
</tr>
<tr>
<td>Olmsted County (4)</td>
<td>All consecutive patients hospitalized at Mayo Clinic hospitals from 1987-2001 (ICD code 428 and DRG code 127)</td>
<td>–</td>
<td>≥50</td>
<td>41.3</td>
<td>–</td>
<td>–</td>
<td>29%</td>
<td>Mortality rate at 1 yr</td>
<td>Increased prevalence of HFpEF with similar rate of death over a 15-yr period</td>
</tr>
<tr>
<td>ADHERE (96)</td>
<td>AHF as new-onset HF or decompensated chronic HF with symptoms requiring hospitalization; ICD-9 discharge diagnosis of HF</td>
<td>63</td>
<td>≥40</td>
<td>21 (1st ECG)</td>
<td>–</td>
<td>–</td>
<td>2.8%</td>
<td>In-hospital mortality</td>
<td>In-hospital mortality was lower in patients with HFpEF vs. HFrEF</td>
</tr>
<tr>
<td>OPTIMIZE-HF (22)</td>
<td>Hospitalized new-onset or worsening HF as primary cause of admission or significant HF symptoms that developed during hospitalization with HF as primary discharge diagnosis</td>
<td>–</td>
<td>≥40</td>
<td>33</td>
<td>502</td>
<td>–</td>
<td>35.3%</td>
<td>Post-discharge mortality/rehospitalization at 60-90 days</td>
<td>HFpEF and HFrEF had similar lengths of hospital stay, in-hospital mortality was lower in HFpEF</td>
</tr>
<tr>
<td>MAGGIC (24)</td>
<td>Meta-analysis of observational studies and RCTs through 2006, with eligible studies including patients with HF and death from any cause where EF criterion was not used for study entry</td>
<td>–</td>
<td>≥50</td>
<td>27</td>
<td>–</td>
<td>–</td>
<td>12.1 per 100 patient-ys</td>
<td>Death from any cause</td>
<td>HFpEF patients have a lower risk of death than patients with HFpEF but absolute mortality in HFpEF is still high</td>
</tr>
<tr>
<td>GWTG-HF (5)</td>
<td>Hospitalization for acute, decompensated HF on the basis of clinical diagnosis</td>
<td>54</td>
<td>≥50</td>
<td>34</td>
<td>551</td>
<td>5,495</td>
<td>2.5%</td>
<td>In-hospital mortality</td>
<td>Hospitalization for HFpEF is increasing relative to HFrEF, with in-hospital mortality for HFpEF declining over study period</td>
</tr>
</tbody>
</table>

*NP levels are median levels unless otherwise specified, and if used as inclusion criteria they are listed with > or < symbols. †Data are in percentages or 100 patient-years and from placebo groups in clinical trials unless otherwise noted. ‡RELAX-AHF event rate is cardiovascular death or HF/renal failure hospitalization through day 60. ADHERE = Acute Decompensated Heart Failure Registry; AHF = acute heart failure; ALDO-DHF = Aldosterone receptor blockade in Diastolic Heart Failure; BL = baseline; BNP = B-type natriuretic peptide; CHARM-PRESERVED = Candesartan in Patients With Heart Failure and Preserved Left Ventricular Systolic Function; CV = cardiovascular; DD = diastolic dysfunction; DIG-PEF = Digitals Intervention Group-Preserved Ejection Fraction; DRG = diagnosis-related group; DX = diagnosis; EDHF = Effect of ivabradine versus placebo on cardiac function and on capacity to perform exercise in patients suffering from diastolic heart failure; E/E′ = peak early transmural ventricular filling velocity/early diastolic tissue Doppler velocity; echo = echocardiography; EF = ejection fraction; eGFR = estimated glomerular filtration rate; ELANDD = Effects of Long-term Administration of Nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with Diastolic Dysfunction; Ex-DHF = Exercise Training in Diastolic Heart Failure; GWTG-HF = Get With the Guidelines Heart Failure; ICD = International Classification of Diseases; I-PRESERVE = Ibrusartan in patients with heart failure and preserved ejection fraction; IV = intravenous; J-DHF = Japanese Diastolic Heart Failure; LAE = left atrial enlargement; LVMI = left ventricular mass index; LVH = left ventricular hypertrophy; MAGGIC = Meta-analysis Global Group in Chronic Heart Failure; NSR = normal sinus rhythm; NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart Association; OPTIMIZE-HF = Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure; PARAGON-HF = Efficacy and Safety of LCZ696 Compared to Valvartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction; PARAMOUNT = Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection fraction; PEP-CHF = Perindopril in elderly people with chronic heart failure; RAAM-PEF = Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction; RCT = randomized controlled trial; RELAX = The Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction; RELAX-AHF = RELAX in Acute Heart Failure; SENIORS = Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisations in Seniors with Heart Failure; SHIFT-PEF = Systolic Heart Failure Treatment With the If Inhibitor Ivasubin Preserved; SIDERATES-PRESERVED = Phase Ib Safety and Efficacy Study of Four Dose Regimens of BAY101189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure; TOPCAT = Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist; VAS-AUC = visual analog scale-area under curve; VO₂ = peak oxygen consumption; 6MWD = 6 min walk distance; other abbreviations as in Table 1.
PRIOR HF HOSPITALIZATION

Prior hospitalization for HF is a powerful predictor of future outcomes. Investigators pooled the CHARM clinical trials and used a time-updated Cox proportional hazards model to show that the mortality rate increased after HF hospitalization for upwards of 6 months from time of discharge to randomization (26). This observation was also independent of EF. Longer hospitalization and repeat hospitalization also increased the risk of mortality. The time period early after discharge from hospitalization for HF represents a particularly high-risk window for mortality. This high-risk period may also represent an opportunity to enrich event rates in clinical trials (28). A large population study in Ontario, Canada, reported 1-year HF readmission rates of 16.1% and 13.5% (p = 0.09) for HFrEF and HFpEF, respectively, whereas the unadjusted combined 1-year endpoint of death and HF readmission was 36.1% and 31.1% for HFrEF and HFpEF, respectively (p = 0.01) (29). A recent analysis of the CHARM trials revealed that event rates for mortality and hospitalization were higher in patients with previous HF hospitalization compared with those without prior HF hospitalization. Specifically, the time interval between prior hospitalization and randomization was inversely related to the risk for mortality and hospitalization (i.e., patients more recently discharged have higher risk of death and readmission), and the overall rates between HFrEF and HFpEF were similar (26). Patients hospitalized for HF within the previous 6 months in the I-PRESERVE (Irbesartan in Heart Failure with Preserved Systolic Function) trial had 10.5 events per 100 patient-years compared with 4.4 events per 100 patient-years in those not recently hospitalized for HF (18,30).

Recent HFpEF trials have incorporated the inclusion criterion of prior hospitalization for HF on the basis of the high risk associated with recent HF hospitalization, as identified in the CHARM program (26), but this inclusion criterion has also complicated the interpretation of trial results. The recent TOPCAT trial demonstrated that there were regional differences in how patients entered the trial, specifically related to the HF hospitalization criterion. In addition to ≥1 sign and symptom of HF, an EF ≥45%, and controlled systolic blood pressure, patients were required to have a history of hospitalization within the previous 12 months, with management of HF a major component of the care provided or an elevated NP level within 60 days before randomization (B-type natriuretic peptide [BNP] ≥100 pg/ml or N-terminal pro-B-type natriuretic peptide [NT-proBNP] ≥360 pg/ml). In the Americas, 39.6% of patients qualified for the trial on the basis of HF hospitalization within the preceding 12 months compared with 60.4% of patients from Eastern Europe (19). Unadjusted Cox models by geographic region and treatment group revealed that patients enrolled in the Americas control group had a primary outcome event rate of 31.8%, compared with 8.4% in patients enrolled in the Eastern European control group. Furthermore, post-hoc analyses of TOPCAT revealed a 4-fold difference in event rate in patients enrolled in Russia and Georgia compared with the Americas, where the primary outcomes of cardiovascular death and hospitalization were significantly reduced by spironolactone (31). TOPCAT inclusion criteria required HF to be a major component of the prior hospitalization, whereas I-PRESERVE and CHARM required that HF was the primary cause of hospitalization. This subtle difference defining previous HF hospitalization inclusion criteria may have contributed to the low event rates seen in Russia and Georgia in TOPCAT despite the high percentage of patients with a history of hospitalization (13,18,19). These data support observations seen in other international clinical trials whereby the patients enrolled in different regions/countries have distinct underlying characteristics, treatment protocols/standards, and event rates (30–34). Hospitalization for HF is an important inclusion criterion that can drive increased event rates in clinical trials, but the clinical definition of HF is subjective, and nuances pertaining to whether HF is the primary cause of hospitalization or not are subject to interpretation. Different definitions, interpretations, and practice standards may potentially lead to different event rates.

The use of prior hospitalization as an inclusion criterion in HFpEF clinical trials can and should be a powerful driver of event rates. Using hospitals for HF as remote as 12 months has proven successful, but event rates occur early after discharge; thus, the use of hospitalizations for HF within 6 months will increase event rates. Geographical and international differences in the definition and treatment of patients with HFpEF necessitates further confirmation of clinical HFpEF that can include adjudication or combining HF hospitalization with a specific threshold NP level. Confirming HF hospitalizations or combining HF hospitalization and NP level entry criteria will decrease variability in HFpEF patients and enrich HFpEF event rates.

CLINICAL DIAGNOSIS OF HF

HF is diagnosed on the basis of a clinical assessment and physical examination, along with supporting data
from the chest radiograph and additional testing. Despite the added clinical and laboratory information, the diagnosis remains largely subjective, with clinical gestalt on the basis of history, physical examination, and routinely-obtained laboratory and hemodynamic measurements. The traditional physical examination findings associated with HF, including paroxysmal nocturnal dyspnea, jugular venous distension, and pulmonary rales have sensitivities for left ventricular dysfunction ranging from 17% to 39%, whereas their specificities range from 77% to 98% (35,36). The NYHA functional class is a subjective measurement used in HF trials that is strongly associated with worse outcomes in patients with HFrEF and HFpEF (37-39). Ultimately, the decision to hospitalize a patient for HF is determined by the physician’s interpretation of the patient’s overall status. Dyspnea severity is the inherent symptom that influences decision-making. A recent analysis revealed that 50% of patients had dyspnea at rest and that these patients had increased rates of comorbidities, mortality, and HF readmission risk (40).

There are differences in presentations and management across geographical regions that can challenge the design and interpretation of clinical trial results (41). Dyspnea responds quickly to intravenous diuretic agents, with upwards of three-fourths of patients responding within 6 h sitting upright versus 47% supine (42). There are multiple dyspnea scales; those commonly used are the 5- and 7-point Likert scales and the 10-cm visual analog scale. A post-hoc analysis of URGENT (Ularitide Global Evaluation in Acute Decompensated Heart Failure)-Dyspnoea trial revealed that up to 40% of patients did not have improved dyspnea in the first 6 h; for those who did improve, patient characteristics differed across all 3 scales, with the c-index ranging from 0.71 to 0.83, suggesting that improvement in dyspnea may differ from scale to scale (43). The RELAX-AHF (RELAXin in Acute Heart Failure) trial evaluating serelaxin used a visual analog scale area under the curve (VAS-AUC) endpoint to assess if serelaxin-treated patients would have improved dyspnea from baseline dyspnea, congestion on chest radiograph, and elevated NP levels to day 5 of the VAS-AUC, as well as assessing the proportion of patients with moderate or marked dyspnea by the Likert scale during the first 24 h (44). Dyspnea relief, measured by VAS-AUC from baseline to day 5, was improved in the overall population and in HFrEF and HFpEF compared with placebo; however, dyspnea relief at 24 h using the Likert scale was significantly improved in HFpEF patients compared with placebo, but not in HFrEF with treatment (interaction p = 0.03). The primary dyspnea endpoint of 448 mm improvement using the VAS-AUC score was significant (p = 0.007); however, the coprimary endpoint using the Likert scale endpoint was not significant through 5 days (p = 0.7). The dyspnea scoring tools vary from tool to tool and may not always correspond to hard outcomes. The clinical diagnosis of HF on the basis of physician assessment, combined with the use of auxiliary tools, such as NYHA functional classification and dyspnea scores, will enhance HFpEF clinical trials with patients experiencing HF symptoms. In patients without clear HF, adding together dyspnea severity, acute HF diagnostic prediction models, clinical assessment, and NP levels has excellent diagnostic accuracy (45).

NP LEVELS

NP levels, such as BNP and its cosecreted biologically-inactive compound, NT-proBNP, are useful markers for diagnosing HF and provide prognostic information for patients presenting with dyspnea. In more recent HFpEF trials, NP levels have been used as key inclusion criteria to: 1) increase the specificity of the HFpEF diagnosis; and 2) select patients at higher risk. Post-hoc analyses from I-PRESERVE reveal that NT-proBNP is the most powerful independent factor for the primary outcome of all-cause mortality or cardiovascular hospitalization in patients with HFpEF (46,47). The PEP-CHF (Perindopril in Elderly People with Chronic Heart Failure) trial demonstrated an increased number of deaths and hospitalization for HF with higher quartiles of NT-proBNP levels (17). In the TOPCAT trial, placebo-group patients enrolled on the basis of NP level had primary outcome event rates of 23.6% compared with 19.1% in patients enrolled on the basis of hospitalization in the past year (Table 2) (19). Using NP-level thresholds for HFpEF clinical trial entry criteria have driven the HFpEF trials with higher event rates.

The COACH (Coordinating study evaluating Outcomes of Advising and Counselling in Heart Failure) substudy confirmed that NP levels are lower in patients with HFpEF compared with HFrEF, although the clinical outcomes were similar for a given BNP level (48). NP levels are also markers of the stage of disease and may potentially guide selection of patients in the “modifiable” zone, which identifies patients who may be neither “too well” nor “too sick” to benefit from an intervention. A post-hoc analysis of I-PRESERVE demonstrated that patients with NT-proBNP levels above the median of 339 pg/ml were independently associated with the primary endpoint of all-cause mortality and cardiovascular hospitalizations, whereas patients with NT-proBNP levels
below the median had beneficial effects from irbesartan, even after adjustment for 20 covariates (49).

In the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction (RELAX) trial evaluating phosphodiesterase-5 inhibition in patients with HFpEF, the median NT-proBNP levels (648 pg/ml) were even higher than in I-PRESERVE with similar results: no improvement in the primary endpoints of peak oxygen consumption (VO₂) or 6-min walk distance (49,50). The I-PRESERVE and the RELAX trials suggest that there is an upper boundary for a modifiable zone, above which a more advanced disease state exists where therapies may provide little, if any, benefit. In the ALDO-DHF (Aldosterone receptor blockade in Diastolic Heart Failure) trial, the median NT-proBNP level of 148 pg/ml demonstrated improvement of 1 coprimary endpoint, E/e′, but no improvement in the other coprimary endpoint, change in peak VO₂, suggesting the possibility of a lower boundary where patients are too well to benefit from therapy, in addition to an upper boundary (51).

The cutoff for NPs provides a distinct opportunity to increase the specificity of the diagnosis of HFpEF as well as event rates; however, choosing too high of a level will potentially identify patients too advanced in their disease state to benefit from interventions such as renin-angiotensin aldosterone system therapy (48).

NP levels are highly affected by the confounding comorbidities of atrial fibrillation, renal insufficiency, and obesity. NP levels are lower in obese patients with HFpEF and are independently associated with a favorable adiposity profile (52). Compared with patients with normal body mass index, NP levels are significantly lower in obese and overweight patients after adjustment for important clinical characteristics, including atrial fibrillation (median values of 608, 227, and 396 pg/ml, respectively) (53,54). For example, the NT-proBNP level was revised in the RELAX trial evaluating sildenafil secondary to the “falsely” low NP levels found in obese patients with hemodynamically-validated HFpEF. NP levels are known to be higher in patients with atrial fibrillation (55); however, patients with atrial fibrillation and obesity have an inverse relationship between body mass index and circulating levels of NT-proBNP, suggesting that the underlying pathophysiology of obesity may reduce NP levels (56). HFpEF patients with renal impairment are known to have elevated NP levels, with NT-proBNP rising more than BNP; more than 79% of HFpEF patients with BNP levels >1,000 pg/ml have chronic renal insufficiency (57,58).

Choosing a threshold and ceiling level for trial entry on the basis of NP level requires considering several key factors for success: 1) the tradeoff between specificity and sensitivity for the diagnosis of HFpEF; 2) feasibility of patient recruitment; 3) clinical setting (acute decompensated HFpEF vs. chronic stable HFpEF); and 4) comorbidities. More recent clinical trials have raised the entry criteria for NP from TOPCAT levels of 100 and 360 pg/ml for BNP and NT-proBNP, respectively, to PARAMOUNT’s NT-proBNP threshold of 400 pg/ml (19,20). The PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure) trial used a cutoff of 150 and 600 pg/ml, respectively, for BNP and NT-proBNP for patients without an HF hospitalization in the previous 12 months and 100 and 400 pg/ml, respectively, for patients with a HF hospitalization in the previous 12 months (59). NP levels are 1 of the key inclusion criteria that are most specific for patients with HFpEF with resultant increases in event rates. Careful adjustment upward or downward of NP threshold on the basis of comorbidities will enrich the preferred HFpEF phenotype and result in higher event rates.

**Atrial Fibrillation**

Atrial fibrillation is 1 of the most common comorbidities in patients with HFpEF and coexists in 21% to 34% of patients in large registries and 4% to 61% of patients in HFpEF clinical trials (Table 2). HFpEF patients with atrial fibrillation are older, have higher NP levels, larger left atrial volume indexes, and are independently associated with death after adjustment for covariates compared with HFpEF patients in sinus rhythm (60). The PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized for Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function) trial is 1 of many with a high enrollment of patients with HFpEF in the setting (acute decompensated HFpEF vs. chronic stable HFpEF) and with several key factors for success: 1) the tradeoff between specificity and sensitivity for the diagnosis of HFpEF; 2) feasibility of patient recruitment; 3) clinical setting (acute decompensated HFpEF vs. chronic stable HFpEF); and 4) comorbidities. More recent clinical trials have raised the entry criteria for NP from TOPCAT levels of 100 and 360 pg/ml for BNP and NT-proBNP, respectively, to PARAMOUNT’s NT-proBNP threshold of 400 pg/ml (19,20). The PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure) trial used a cutoff of 150 and 600 pg/ml, respectively, for BNP and NT-proBNP for patients without an HF hospitalization in the previous 12 months and 100 and 400 pg/ml, respectively, for patients with a HF hospitalization in the previous 12 months (59). NP levels are 1 of the key inclusion criteria that are most specific for patients with HFpEF with resultant increases in event rates. Careful adjustment upward or downward of NP threshold on the basis of comorbidities will enrich the preferred HFpEF phenotype and result in higher event rates.
have higher levels of NP and larger left atrium, independent of HF). Furthermore, some have argued that atrial fibrillation should be considered part and parcel of the HFpEF disease syndrome because almost two-thirds of HFpEF patients have atrial fibrillation during the course of their disease: approximately 29% of patients with HFpEF have atrial fibrillation before diagnosis; 23% have atrial fibrillation at the time of diagnosis; and 32% go on to develop atrial fibrillation within 3 to 4 years of follow-up (60). In PARAMOUNT, the mandate for an NT-proBNP cutoff for entry resulted in an over-representation of patients with atrial fibrillation, in whom higher levels of NT-proBNP are expected and are related to atrial fibrillation and the resultant increased left atrial size and circulatory volume, leading to increased release of NPs. If, as expected, more patients have atrial fibrillation without true HFpEF, then there would be a significant effect on PARAMOUNT’s goal to detect LCZ696’s efficacy in patients with HFpEF, as LCZ696 is not known to affect the underlying pathophysiology of atrial fibrillation. The significant number of enrolled patients with atrial fibrillation led to a cap on the absolute percentage of patients with atrial fibrillation that could be recruited.

Strategies to address this dilemma include: 1) introduction of a cap on the proportion of patients with atrial fibrillation who can be recruited; and 2) using different NT-proBNP cutoffs for those with and without atrial fibrillation.

HEMODYNAMICS

Hemodynamics, measured invasively and non-invasively, yield an objective assessment of pressures in the venous circulation. Central venous pressure increases when increased circulatory volume occurs from tricuspid regurgitation or right ventricle failure,
Methodological Recommendations to Enhance Clinical Trial Success Through Increased Event Rates

**Ideal HFpEF Trial Candidate Criterion**

- **EF**
  - Use an EF cutoff ≥50% to reduce the number of patients who may represent a different disease phenotype (e.g., patients who have recovered their EF)

- **NP Levels**
  - Use entry criteria thresholds and limits to choose patients with the most modifiable substrate to optimize event rates and minimize patients with less modifiable substrate

- **Comorbidities**
  - Consider limiting patients with specific comorbidities such as atrial fibrillation through use of a higher natriuretic peptide level entry criteria with a cap on the total number of patients with atrial fibrillation

**Increase HF diagnosis accuracy for a universal phenotype**

- **HF hospitalization**
  - Define prior HF hospitalization by consistent criteria to enrich event rates and standardize entry criteria to facilitate trial comparison and shared lessons learned

- **Clinical HF diagnosis**
  - Define the clinical diagnosis of heart failure with specific criteria that accurately represents the HFpEF phenotype across international and geographical regions

- **Hemodynamics**
  - Use invasive/ noninvasive hemodynamics and CPET measurements in smaller populations or subgroups to investigate new concepts and confirm or exclude unclear diagnoses

**Improve clinical trial design**

- Include important patient-centered endpoints (e.g., total hospitalization burden instead of only first hospitalization) to enhance important clinical and regulatory endpoints

---

Previous and ongoing clinical trial inclusion criteria and methodological considerations are presented with recommendations to highlight the complexity of clinical trial design with associated recommendations to enhance event rates and future clinical trial success.

CPET = cardiopulmonary exercise testing; EF = ejection fraction; HF = heart failure; HFpEF = heart failure with preserved ejection fraction; NP = natriuretic peptide; NT-proBNP = N-terminal pro-B-type natriuretic peptide.

---


---

and can be estimated fairly accurately through echocardiography. Hemodynamic measurements help discern which patients have the diagnosis of HF when the usual selection criteria are not conclusive. Pulmonary hypertension, defined as pulmonary artery systolic pressure (PASP) >35 mm Hg, is frequently caused by left-sided HF, is derived from the tricuspid velocity, and is highly prevalent, with estimates as high as 83% of patients with HFpEF (62), whereas pulmonary capillary wedge pressure (PCWP) is estimated from the ratio of early transmural flow velocity to early mitral annular diastolic velocity. Normal filling pressures and other hemodynamic parameters, such as PCWP, PASP, and left ventricular end-diastolic pressure at rest followed by normal filling pressures during exercise, exclude the diagnosis of HF. In contrast, if filling pressures increase in proportion to the increase in PCWP, then a diagnosis of HFpEF is suggested (63–65). Other related diagnoses, such as pulmonary arterial hypertension, can also be clearly identified during right heart catheterization.

However, outside of small studies evaluating hemodynamics in patients with equivocal diagnoses, invasive hemodynamic measurements are infrequently used, and there is limited data from clinical trials confirming that these measurements enhance event rates. The RELAX trial evaluating phosphodiesterase-5 inhibition utilized an alternative entry criterion for elevated left ventricular end-diastolic pressure or PCWP if other criteria were not met in a small number of unreported patients (50). Cardiopulmonary exercise testing (CPET) provides additive information to hemodynamics that may help exclude HF with normal tests and confirm or suggest a HF diagnosis with abnormal results (66). CPET measurements obtained during exercise, including the gas exchange parameters, peak VO2, and the slope of the relationship between ventilation and carbon dioxide production, are independently associated with mortality and are strong independent predictors of mortality (39). A study evaluating serelaxin demonstrated significant reductions in peak PCWP without changes in cardiac index, and a CPET with echocardiography study in patients with HFpEF treated with ivabradine, which revealed improved metabolic equivalents, peak VO2, and reduced E/e’, provided the impetus to pursue larger clinical trials on these 2 promising therapies (67,68).

Guazzi et al. (69) demonstrated significant improvements in mean pulmonary artery pressure, right atrial pressure, pulmonary vascular resistance, tricuspid annular systolic excursion, and EF using invasive hemodynamics obtained in 44 patients with HFpEF randomized to placebo or sildenafil with benefits through 12 months of follow-up in the patients with baseline evidence of chronically-elevated left ventricular filling pressures. Guazzi’s work led to further investigation of sildenafil’s phosphodiesterase-5 inhibition in the RELAX clinical trial of 216 patients with endpoints closely related to hemodynamics: change in peak VO2 and 6-min walk distance (50). After 24 weeks, there were no significant changes in peak VO2 or 6-min walk distance; however, hemodynamic-related measurements of E/e’, left atrial volume index, and PASP were
consistent with chronically-elevated left ventricular filling pressures. Cardiovascular hemodynamics obtained from noninvasive and invasive measurements are very helpful for the confirmation or exclusion of patients who do not meet diagnostic criteria from the usual selection criteria. However, the actual effect of adding hemodynamic measurements to drive event rates in clinical trials remains unknown, and future inclusion in pilot studies and clinical trials are needed to verify their value.

LESSONS LEARNED

HF remains a clinical diagnosis that may be enhanced by weighing and/or limiting the patient selection criteria discussed herein, including EF, prior HF hospitalization, NP levels, comorbidities such as atrial fibrillation, clinical diagnosis of HF, and hemodynamics (Figure 1). In addition to balancing patient selection criteria, clinical trial design, implementation, and integration of novel diagnostic techniques are paramount to discovering future therapies for HFpEF (Figure 2). Enrolling patients quickly prevents crossover to the treatment intervention, as evidenced by a restrictive analysis of PEP-CHF that trended toward clinical significance (p = 0.055) for the primary endpoint of all-cause mortality and unplanned HF hospitalization in the first year, with the secondary endpoint of unplanned hospitalization for HF significant (p = 0.032) (17). Implementing important patient-centered outcomes through the use of all hospitalizations, instead of only first hospitalizations, can drive important event rates (70). Factoring in the expected differences in event rates across geographical and international regions on the basis of past event rates related to differences in clinical and socioeconomic practices across the world (Table 2), as evidenced by post-hoc analyses from the TOPCAT trial demonstrating clinical benefit in the Americas (hazard ratio: 0.82) compared with Russia/Republic of Georgia (hazard ratio: 1.1) will allow for proper statistical power to detect meaningful differences (19,31).

Recent studies evaluating new imaging techniques measuring impaired systolic function in patients with HFpEF through 3-dimensional speckle, left atrial, and longitudinal strain analyses, which are associated with mortality and may provide opportunities to enhance patient selection and event rates (71–76). Emerging and novel biomarkers, such as cystatin C, galectin-3, and growth differentiation factor-15, may help phenotype, risk-stratify, and identify patients with or at risk for HFpEF (77–79). Evidence continues to mount from studies that evaluated isolated comorbidities, such as coronary disease (80) and diabetes mellitus (81), in patients with HFpEF, demonstrating worse mortality, although splitting the heterogeneous HFpEF population into targeted groups with distinct phenotypes may lead to therapeutic advances (82,83). Shah et al. (84) recently used statistical learning algorithms in 400 patients with HFpEF to perform an unbiased clustering analysis of dense phenotypic data to “phenomap” patients with HFpEF into more homogeneous subclasses. Combinations of “omics,” cluster analyses, and phenomapping result in novel classifications of HFpEF that may simplify this heterogeneous population into discernable classifications that ultimately allow for targeted pharmaceutical therapies (85,86). Integration of lessons learned from previous HFpEF clinical trials with current patient selection criteria and emerging and novel imaging, biomarker, and phenotype classification schema provide a unique scaffold to advance HFpEF clinical trial success.

CONCLUSIONS

Promising new therapeutic options on the basis of sound scientific rationale and observational data, such as the recently-published study on angiotensin-neprilysin inhibitors (59), may prove to benefit patients with HFpEF. However, clinical trials in HFpEF using standard, mortality-reducing therapies known in HFrEF have thus far been neutral. To optimize clinical trial effectiveness, trials in patients with HFpEF should consider inclusion of patients with the common comorbidities that drive HFpEF’s underlying pathophysiology through the balanced use of the following key inclusion and exclusion criteria: universal EF cutpoint; appropriate NP-level thresholds; limited number of patients with atrial fibrillation (with a higher NP cut-point); and use of a clearly-defined history of HF and diagnosis of previous HF (Central Illustration). Attaining hemodynamic measurements related to HFpEF through the use of echocardiography, cardiopulmonary exercise testing, and invasive hemodynamics may complement or validate challenging patients. Thoughtful clinical trial design that incorporates the lessons learned from previous and ongoing clinical trials in patients with HFpEF will provide the trial landscape necessary to determine if future therapies actually improve the outcomes and/or quality of life in patients with HFpEF.
REFERENCES


8. Authors/Task Force Members, Dickstein K, Cohen-Solal A, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388–442.


KEY WORDS clinical protocols, methodology, natriuretic peptides, patient selection